Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.56 |
| ▸ | LOX | P28300 | 8/20 | 0.56 |
| ▸ | LOXL2 | Q9Y4K0 | 6/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14572440 | 0.80 | HTR6 (0.56) | HTR6LOXLOXL2MAOASMN1; SMN2 | |
| (Phenylsulfonyl)Benzene SCHEMBL25435825 | 0.78 | HTR6 (0.93) | HTR6LOXLOXL2MAOASMN1; SMN2 | |
| SCHEMBL16797498 | 0.76 | HTR6 (0.56) | HTR6LOXLOXL2MAOASMN1; SMN2 | |
| SCHEMBL8825214 | 0.76 | LOX (0.61) | HTR6LOXLOXL2MAOA | |
| SCHEMBL4250025 | 0.76 | HTR6 (0.56) | HTR6LOXLOXL2MAOAKMT2A | |
| SCHEMBL14502555 | 0.76 | HTR6 (0.56) | HTR6LOXLOXL2MAOAKCNH2 | |
| SCHEMBL787866 | 0.76 | HTR6 (0.56) | HTR6LOXLOXL2MAOAKMT2A | |
| SCHEMBL9235944 | 0.76 | LOX (0.61) | HTR6LOXLOXL2MAOA | |
| SCHEMBL11125174 | 0.76 | LOX (0.53) | HTR6LOXLOXL2MAOASMN1; SMN2 | |
| SCHEMBL12619971 | 0.76 | LOX (0.70) | HTR6LOXLOXL2MAOALOXL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017141049-A1 | METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2017-08-24 | — | — | WO | disclosed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| CN-1040213-C | Diaryl 5,6-fusedheterocyclic acids as leukotriene antagonists | MERCK FROSCT CANADA INC (CA) | 1998-10-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | HTR6 2387/4885LOX 1603/4885LOXL2 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.